LB1148 is a broad-spectrum serine protease inhibitor designed to neutralize digestive enzymes and potentially reduce intestinal damage.
According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.
The VITAL randomized clinical trial tested vitamin D and marine omega-3 fatty acid supplements in the primary prevention of cancer and cardiovascular disease.
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
The designation is supported by data from the 12-week, randomized, double-blind phase 2 FILLMORE trial.
Kineret is an interleukin-1 receptor antagonist.
The vote was mixed when the data was reviewed for younger patients.
Bebtelovimab is currently authorized for emergency use for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
Nearly a third of female oncologists surveyed said they experienced some form of discrimination during pregnancy.
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
The EMPA-KIDNEY trial enrolled more than 6600 patients 18 years of age and older with CKD at risk of kidney disease progression.
The 2022 CDC Clinical Practice Guideline is intended to help clinicians weigh the benefits and risks of opioids and alternative pain treatments for outpatients.
Iron deficiency associates with adverse outcomes in patients on peritoneal dialysis, regardless of anemia status.
The association is revealed in a study of more 444,000 US veterans with new-onset chronic kidney disease.
Study finds that medication administration processes (MAPs) are frequently interrupted and these disruptions may create an opportunity for patient harm.
TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore physiologic levels of PTH for 24 hours each day.
The approval was supported by data from a phase 2 trial that included 70 patients aged 12 to less than 18 years with chronic HBV infection.
Researchers sought to determine whether prophylaxis with octocog alfa would lead to stable bleeding rates in patients with hemophilia A.
An ultrasound monitor that can stick to the skin and provides sharp images of blood vessels and internal organs is among the latest medical remote monitoring technologies under development.
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.